RESUMEN
Attempts to treat Alzheimer's disease with immunotherapy against the ß-amyloid (Aß) peptide or with enzyme inhibitors to reduce Aß production have not yet resulted in effective treatment, suggesting that alternative strategies may be useful. Here we explore the possibility of targeting the toxicity associated with Aß aggregation by using the recombinant human (rh) Bri2 BRICHOS chaperone domain, mutated to act selectively against Aß42 oligomer generation and neurotoxicity in vitro. We find that treatment of Aß precursor protein (App) knockin mice with repeated intravenous injections of rh Bri2 BRICHOS R221E, from an age close to the start of development of Alzheimer's disease-like pathology, improves recognition and working memory, as assessed using novel object recognition and Y maze tests, and reduces Aß plaque deposition and activation of astrocytes and microglia. When treatment was started about 4 months after Alzheimer's disease-like pathology was already established, memory improvement was not detected, but Aß plaque deposition and gliosis were reduced, and substantially reduced astrocyte accumulation in the vicinity of Aß plaques was observed. The degrees of treatment effects observed in the App knockin mouse models apparently correlate with the amounts of Bri2 BRICHOS detected in brain sections after the end of the treatment period.
Asunto(s)
Enfermedad de Alzheimer , Humanos , Ratones , Animales , Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/metabolismo , Encéfalo/metabolismo , Chaperonas Moleculares/genética , Chaperonas Moleculares/metabolismo , Placa Amiloide/tratamiento farmacológico , Placa Amiloide/metabolismo , Modelos Animales de Enfermedad , Ratones Transgénicos , Precursor de Proteína beta-Amiloide/metabolismoRESUMEN
Human integral membrane protein 2B (ITM2B or Bri2) is a member of the BRICHOS family, proteins that efficiently prevent Aß42 aggregation via a unique mechanism. The identification of novel Bri2 BRICHOS client proteins could help elucidate signaling pathways and determine novel targets to prevent or cure amyloid diseases. To identify Bri2 BRICHOS interacting partners, we carried out a 'protein fishing' experiment using recombinant human (rh) Bri2 BRICHOS-coated magnetic particles, which exhibit essentially identical ability to inhibit Aß42 fibril formation as free rh Bri2 BRICHOS, in combination with proteomic analysis on homogenates of SH-SY5Y cells. We identified 70 proteins that had more significant interactions with rh Bri2 BRICHOS relative to the corresponding control particles. Three previously identified Bri2 BRICHOS interacting proteins were also identified in our 'fishing' experiments. The binding affinity of Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), the top 'hit', was calculated and was identified as a strong interacting partner. Enrichment analysis of the retained proteins identified three biological pathways: Rho GTPase, heat stress response and pyruvate, cysteine and methionine metabolism.
Asunto(s)
Péptidos beta-Amiloides , Proteínas Portadoras , Proteínas Adaptadoras Transductoras de Señales , Amiloide/metabolismo , Péptidos beta-Amiloides/metabolismo , Humanos , Fenómenos Magnéticos , Unión Proteica , ProteómicaRESUMEN
A new generation of ligands designed to interact with the α-helix/ß-strand discordant region of the amyloid-ß peptide (Aß) and to counteract its oligomerization is presented. These ligands are designed to interact with and stabilize the Aß central helix (residues 13-26) in an α-helical conformation with increased interaction by combining properties of several first-generation ligands. The new peptide-like ligands aim at extended hydrophobic and polar contacts across the central part of the Aß, that is, "clamping" the target. Molecular dynamics (MD) simulations of the stability of the Aß central helix in the presence of a set of second-generation ligands were performed and revealed further stabilization of the Aß α-helical conformation, with larger number of polar and nonpolar contacts between ligand and Aß, compared to first-generation ligands. The synthesis of selected novel Aß-targeting ligands was performed in solution via an active ester coupling approach or on solid-phase using an Fmoc chemistry protocol. This included incorporation of aliphatic hydrocarbon moieties, a branched triamino acid with an aliphatic hydrocarbon tail, and an amino acid with a 4'- N, N-dimethylamino-1,8-naphthalimido group in the side chain. The ability of the ligands to reduce Aß1-42 neurotoxicity was evaluated by gamma oscillation experiments in hippocampal slice preparations. The "clamping" second-generation ligands were found to be effective antineurotoxicity agents and strongly prevented the degradation of gamma oscillations by physiological concentration of monomeric Aß1-42 at a stoichiometric ratio.
Asunto(s)
Péptidos beta-Amiloides/toxicidad , Sistemas de Liberación de Medicamentos/métodos , Simulación de Dinámica Molecular , Fragmentos de Péptidos/administración & dosificación , Peptidomiméticos/administración & dosificación , Péptidos beta-Amiloides/antagonistas & inhibidores , Péptidos beta-Amiloides/metabolismo , Animales , Línea Celular Tumoral , Femenino , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Humanos , Ligandos , Masculino , Ratones , Ratones Endogámicos C57BL , Técnicas de Cultivo de Órganos , Fragmentos de Péptidos/antagonistas & inhibidores , Fragmentos de Péptidos/metabolismo , Fragmentos de Péptidos/toxicidad , Peptidomiméticos/metabolismoRESUMEN
Targeting toxicity associated with ß-amyloid (Aß) misfolding and aggregation is a promising therapeutic strategy for preventing or managing Alzheimer's disease. The BRICHOS domains from human prosurfactant protein C (proSP-C) and integral membrane protein 2B (Bri2) efficiently reduce neurotoxicity associated with Aß42 fibril formation both in vitro and in vivo In this study, we evaluated the serum half-lives and permeability into the brain and cerebrospinal fluid (CSF) of recombinant human (rh) proSP-C and Bri2 BRICHOS domains injected intravenously into WT mice. We found that rh proSP-C BRICHOS has a longer blood serum half-life compared with rh Bri2 BRICHOS and passed into the CSF but not into the brain parenchyma. As judged by Western blotting, immunohistochemistry, and ELISA, rh Bri2 BRICHOS passed into both the CSF and brain. Intracellular immunostaining for rh Bri2 BRICHOS was observed in the choroid plexus epithelium as well as in the cerebral cortex. Our results indicate that intravenously administered rh proSP-C and Bri2 BRICHOS domains have different pharmacokinetic properties and blood-brain/blood-CSF permeability in mice. The finding that rh Bri2 BRICHOS can reach the brain parenchyma after peripheral administration may be harnessed in the search for new therapeutic strategies for managing Alzheimer's disease.
Asunto(s)
Péptidos beta-Amiloides/metabolismo , Barrera Hematoencefálica/metabolismo , Encéfalo/metabolismo , Proteínas de la Membrana/sangre , Proteínas de la Membrana/líquido cefalorraquídeo , Péptidos/sangre , Péptidos/líquido cefalorraquídeo , Proteínas Adaptadoras Transductoras de Señales , Animales , Permeabilidad de la Membrana Celular , Péptidos y Proteínas de Señalización Intercelular , Masculino , Proteínas de la Membrana/administración & dosificación , Ratones , Ratones Endogámicos C57BL , Péptidos/administración & dosificación , Dominios Proteicos , Proteína C Asociada a Surfactante PulmonarAsunto(s)
Amiloide/antagonistas & inhibidores , Barrera Hematoencefálica/metabolismo , Glicoproteínas de Membrana/farmacología , Glicoproteínas de Membrana/farmacocinética , Chaperonas Moleculares/farmacología , Chaperonas Moleculares/farmacocinética , Proteínas Adaptadoras Transductoras de Señales , Animales , Barrera Hematoencefálica/patología , Glicoproteínas de Membrana/genética , Ratones , Ratones Transgénicos , Chaperonas Moleculares/genética , Permeabilidad , Proteínas Recombinantes/genética , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/farmacologíaRESUMEN
Chaperone-mediated autophagy (CMA), a subtype of autophagy, delivers select proteins into the lysosome for degradation. Defects in CMA activity have previously been linked with neurodegenerative diseases due to the accumulation of misfolded proteins, but the role of CMA in cancer is currently not well defined. In a recent study, we provide a novel mechanism by which excessive activation of CMA can be exploited as a method to eliminate cancer cells by inducing metabolic catastrophe and delineate a novel strategy to promote the degradation of HK2 (hexokinase 2) in cancer cells.
Asunto(s)
Autofagia/fisiología , Hexoquinasa/metabolismo , Leucemia Mieloide/enzimología , Leucemia Mieloide/patología , Chaperonas Moleculares/metabolismo , Proteolisis , Tirosina Quinasa 3 Similar a fms/antagonistas & inhibidores , HumanosRESUMEN
Hexokinase II (HK2), a key enzyme involved in glucose metabolism, is regulated by growth factor signaling and is required for initiation and maintenance of tumors. Here we show that metabolic stress triggered by perturbation of receptor tyrosine kinase FLT3 in non-acute myeloid leukemia cells sensitizes cancer cells to autophagy inhibition and leads to excessive activation of chaperone-mediated autophagy (CMA). Our data demonstrate that FLT3 is an important sensor of cellular nutritional state and elucidate the role and molecular mechanism of CMA in metabolic regulation and mediating cancer cell death. Importantly, our proteome analysis revealed that HK2 is a CMA substrate and that its degradation by CMA is regulated by glucose availability. We reveal a new mechanism by which excessive activation of CMA may be exploited pharmacologically to eliminate cancer cells by inhibiting both FLT3 and autophagy. Our study delineates a novel pharmacological strategy to promote the degradation of HK2 in cancer cells.
Asunto(s)
Autofagia/fisiología , Hexoquinasa/metabolismo , Leucemia Mieloide/enzimología , Leucemia Mieloide/patología , Chaperonas Moleculares/metabolismo , Proteolisis , Tirosina Quinasa 3 Similar a fms/antagonistas & inhibidores , Benzotiazoles/farmacología , Línea Celular Tumoral , Glucosa/metabolismo , Glucólisis/efectos de los fármacos , Humanos , Lisosomas/patología , Compuestos de Fenilurea/farmacología , Tirosina Quinasa 3 Similar a fms/metabolismoRESUMEN
Heterogeneity within the same tumor type has been described to be complex and occur at multiple levels. Less is known about the heterogeneity at the level of metabolism, within a tumor set, yet metabolic pathways are highly relevant to survival signaling in tumors. In this study, we profiled the glucose metabolism of several non-small cell lung carcinoma (NSCLC) cell lines and could show that, NSCLC display distinct glycolytic metabolism. Genetic and pharmacological perturbation of glycolysis was selectively toxic to NSCLCs with high rates of glycolysis. Furthermore, high expression of hexokinase-2, localized at the mitochondria, was a feature of the NSCLCs dependent on glucose catabolism. Our study provides evidence for quantitative metabolic diversity in NSCLCs and indicates that glucose metabolism provide differential prosurvival benefits to NSCLCs.